Patients' Global Impression of Change (<scp>PGIC</scp>) Score Compared to Monthly Migraine Days to Evaluate Treatment Persistence With Anti‐<scp>CGRP</scp> Monoclonal Antibodies
This study assessed whether continued treatment with anti-CGRP monoclonal antibodies (mAbs) is driven more by reductions in monthly migraine days (MMDs) or patients' global impression of change (PGIC), a patient-reported outcome. Among 169 patients treated with anti-CGRP mAbs, 21.3% discontinued due to ineffectiveness. PGIC responders (≥ 5) at month 12 were 69.8%, whereas MMD responders (≥ 50% reduction) were 59.2%. Both were significantly associated with discontinuation (PGIC: χ<sup>2</sup> = 33.474, φ = 0.445; MMD: χ<sup>2</sup> = 29.884, φ = 0.421; p < 0.0001). PGIC showed a stronger correlation with discontinuation (r<sub>pb</sub> = 0.541) than MMD reduction (r<sub>pb</sub> = 0.470). These findings highlight PGIC as strongly associated with treatment response, supporting the need for PROMs in evaluating migraine treatment effectiveness.
Authors
- Marina Romozzi (ORCID: https://orcid.org/0000-0001-6016-3141)
- Catello Vollono (ORCID: https://orcid.org/0000-0001-9371-8035)
- Luigi Francesco Iannone (ORCID: https://orcid.org/0000-0003-3598-0195)
- Francesco De Cesaris (ORCID: https://orcid.org/0000-0003-0326-4485)
- Paolo Calabresi (ORCID: https://orcid.org/0000-0003-0326-5509)
Institutions
- Università Cattolica del Sacro Cuore (IT)
- University of Modena and Reggio Emilia (IT)
- Agostino Gemelli University Polyclinic (IT)
- Azienda Ospedaliero-Universitaria di Modena (IT)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Publication Details
- Journal
- Annals of Clinical and Translational Neurology
- Published
- 2025-04-17
- DOI
- https://doi.org/10.1002/acn3.70053
- Citations
- 2
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.94